GSK VS VRTX Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

GSK
10/100

GSK returned 3.98% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

VRTX
57/100

VRTX returned 13.96% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 56 of 100.

Analyst Price Targets

GSK
63/100

4 analysts offer 12-month price targets for GSK. Together, they have an average target of 0, the most optimistic target put GSK at 0 within 12-months and the most pessimistic has GSK at 0.

VRTX
80/100

27 analysts offer 12-month price targets for VRTX. Together, they have an average target of 0, the most optimistic target put VRTX at 0 within 12-months and the most pessimistic has VRTX at 0.

Technicals

GSK
10/100

GSK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

VRTX
21/100

VRTX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

GSK
66/100

GSK has missed earnings 3 times in the last 20 quarters.

VRTX
56/100

VRTX has missed earnings 2 times in the last 20 quarters.

Profit

GSK
72/100

Out of the last 20 quarters, GSK has had 20 profitable quarters and has increased their profits year over year on 7 of them.

VRTX
87/100

Out of the last 20 quarters, VRTX has had 20 profitable quarters and has increased their profits year over year on 13 of them.

Volatility

GSK
56/100

GSK has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

VRTX
52/100

VRTX has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / GSK
Healthcare
Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Vertex Pharmaceuticals Inc Summary

Nasdaq / VRTX
Healthcare
Biotechnology
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.